Global Sunitinib Malate Market - 2021-2028
|出版日期||內容資訊||英文 180 Pages
|全球紓癌特Sunitinib Malate市場(2021年∼2028年) Global Sunitinib Malate Market - 2021-2028|
|出版日期: 2021年05月27日||內容資訊: 英文 180 Pages||
紓癌特是一種抗腫瘤劑，用於治療原發性胰腺神經內分泌腫瘤 (P-NET)、胃腸道間質瘤 (GIST) 和腎癌，並抑制多種分子生長受體，由多激酶抑製劑組成，可防止腫瘤擴散。新興國家對胰腺癌認識的提高和胰腺癌患病率的上升正在推動紓癌特市場的增長。
The global sunitinib malate market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Sunitinib Malate is a specific small molecule, orally bioavailable malate salt of the indolinone-based multi-focused receptor tyrosine kinase (RTK) inhibitor asserted by the U.S. Food and Drug Administration for cancer treatment. Sunitinib cases have been approved for treating pancreatic neuroendocrine tumors, gastrointestinal stromal tumour (GIST), and kidney cancer.
The drug comprises an oral multikinase inhibitor that blocks multiple molecular growth receptors and prevents the spread of cancer. The drug stops the extension of vascular endothelial growth factor receptors (VEGFR), platelet-derived extension factor receptors (PDGFR) and KIT.
Sunitinib malate capsules have received the U.S. Food and Drug Administration approval for treating GIST renal cell carcinoma and renal cell carcinoma in January 2006. They also consequently received approval from the European Medicine Agency in July 2006. Two years next, on April 16, 2008, the drug was approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
The sunitinib malate market growth is driven by the increasing prevalence of pancreatic cancer coupled with increasing awareness about pancreatic cancer in emerging countries is expected to drive the market's growth.
Increasing prevalence of pancreatic cancer will drive the market growth
The growing prevalence of pancreatic cancer is a significant driver for the market. As per the American Cancer Society, around 53,000 Americans are diagnosed with pancreatic cancer in 2016, among close to 42,000 of them accede to it. Due to the related inaccessibility of the pancreas, identifying and removing pancreatic growths is more complex than other tumors. As a consequence, the use of sunitinib malate to treat pancreatic tumors is increasing.
The FDA approved sunitinib malate in May 2011 for the treatment of pancreatic neuroendocrine tumors that have proven challenging to extract surgically or have already metastasized.
Furthermore, the convenience of an inadequate quantity of drug therapeutics for the therapy of advanced pancreatic neuroendocrine tumors and poor diagnosis rate in the beginning phases of pancreatic cancer increases the requirement for sunitinib malate in the treatment of pancreatic cancer. Increasing healthcare expenditure and growing population will expand the market. The drugs under pipeline and rising scope for cancer therapy are drivers in the global sunitinib malate market.
The availability of a limited number of drug therapeutic options for the treatment is driving the market growth
Since its primary characterization, pancreatic cancer has remained one of the most deadly and difficult cancers to operate. Pancreatic cancer is the fourth foremost cause of death in the United States, rising in an estimated 38460 deaths annually. Besides few screening tools available to identify this disease at an early stage, 94% of patients will die within five years of treatment, despite decades of research that have led to a more solid understanding of the cellular and molecular signaling pathways in pancreatic cancer cells. Other treatment alternatives have included more sophisticated pancreatic cancer surgeries and combination therapies. While results have recovered modestly for these patients, more efficient treatments are desperately needed. Thus there are very few medications available in the market for there treatment. These factor will drive the market growth in the forecast period.
Side effects coupled with high cost of will hamper the market growth
However, one of the factors acting against the market's growth is the high cost of Sutent. It stands among the most costly drugs currently being marketed, which puts it out of the average consumer's reach in the lack of sufficient reimbursement. For 28 capsules of Sutent, 37.5mg average cash price is $17,968.99. Some side effects of Sutent, such as Hepatotoxicity and Adverse cardiovascular events like heart failure, myocardial infarction and coronary artery bypass grafting, have also been reported during clinical trials, which could discourage drug adoption.
COVID-19 Impact Analysis
According to the CDC, the senior population with underlying severe therapeutic conditions, including people with cancer, might be at higher risk for severe illness from COVID-19. Patients with pancreatic cancer are at higher risk for severe COVID-19 than those without pancreatic cancer.
According to a research article by Hidenori Toyoda et al., published in Hepatology Communications Journal 2020, during the COVID-19 pandemic 2020, strict measures were implemented by the government to prevent the spread of COVID-19, which adversely affected the routine monitoring of cancers. Therefore, these patients were considered in the emergency category during the pandemic. Besides, the increased sales of this drug will foster healthy growth of the market amid COVID-19.
By application, the Sunitinib malate market is classified into pancreatic neuroendocrine tumors, kidney cancer, gastrointestinal stromal tumor, others.
Pancreatic neuroendocrine tumors segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Pancreatic neuroendocrine tumors (NET), also known as islet cell tumors, are rare tumors of the endocrine pancreas. They form due to the hormone-producing cells in the pancreas. About 90% of the non-functional neuroendocrine tumors are cancerous. It was found that about 90% of the patients with pancreatic NET were initially diagnosed with locally advanced or metastatic cancer. Patients with pancreatic NET in an advanced or metastatic stage can survive for one to three years. The disease is rare cancer reported in two to four people per million each year worldwide.
Some pancreatic neuroendocrine tumor cells extend to secrete hormones (known as functional tumors), producing too much of the given hormone in your body. Examples of these types include glucagonoma and gastrinoma. These tumors often do not secrete an excess amount of these hormones (known as nonfunctional tumors).
Functional neuroendocrine tumors create the pancreas to overproduce hormones, consequently making hormone-related symptoms. The majority of NETs are nonfunctional tumors. Nonfunctional tumors do not produce any hormones, so people do not cause any hormone-related indications. As a result, these tumors are typically diagnosed once the tumor is advanced and generates symptoms such as pain or jaundice.
On the basis of therapy, the the Sunitinib Malate Market is classified into targeted therapy radiation therapy, immunotherapy, chemotherapy.
North America region holds the largest market share in the global Sunitinib Malate Market
North America region is dominating the global sunitinib malate market accounted for the largest market share in 2020, owing to the growing incidence of pancreatic cancer in the in the region, the presence of key market players, and the launch of new commodities influence market growth in the region. For instance, the region is emerged as the leading markets for sunitinib malate capsules, which are marketed by Pfizer as Sutent.
Pfizer has market exclusivity over sunitinib malate capsules until 2021, which has made them an important revenue source for Pfizer, which had been losing revenue due to Lipitor's patent expiration in November 2011, estimated at more than US$1 Bn as of 2015.
On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period due to the increase in healthcare expenditure, rising awareness about early diagnosis, high unmet clinical needs of patients, and effective treatment in emerging countries, such as China and India.
The sunitinib malate market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Pfizer, Topcare pharmaceutical Co. Ltd, Nanjing First Pharmaceutical Co. Ltd., J&K Scientific, Target Molecule Corp., Medichem, Biotechnica Pharma Global, Beijing Lunarsun Pharmaceutical Co. LTD, Brawn Laboratories Ltd INDIA, Hetero Drugs Ltd, Hikma Pharmaceutical plc among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the sunitinib malate market globally.
Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.
Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.
The global sunitinib malate market report would provide an access to an approx. 61 market data table, 54 figures and 200 pages.
LIST NOT EXHAUSTIVE